No quarterly revenue total was found in NIKA PHARMACEUTICALS, INC.'s SEC filings.
Nika Pharmaceuticals, Inc. (NIKA) files with the SEC under industry code 2834, Pharmaceutical Preparations. As of Jun 30, 2026 it held $2,932 in cash and investments and $340,624 in total debt.
Revenue
—
Net income
$-19,694
-7.1% vs year-ago quarter
Operating cash flow
$-7,598
+59.0% vs year-ago quarter
Free cash flow
—
EPS
$0.00
Dividend per share
None
Shares outstanding
1.05B
+2.5% vs year-ago quarter
Net cash
$-337,692
Q2 FY2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- NIKA (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- CO
- Headquarters
- Henderson, NV
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1145604
- Former names
- CENTENNIAL GROWTH EQUITIES INC (until Aug 15, 2022)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$19,694 | -$13,359 | -$37,089 | -$7,999 | -$18,381 |
| Net income | -$19,694 | -$13,359 | -$37,089 | -$7,999 | -$18,381 |
| Diluted EPS | $0.00 | $0.00 | -$0.00 | $0.00 | $0.00 |
| Operating cash flow | -$7,598 | -$13,359 | -$38,858 | -$9,329 | -$18,522 |
| Total assets | $9,942 | $20,637 | $20,996 | $23,625 | $31,607 |
| Total liabilities | $340,624 | $331,624 | $318,624 | $284,164 | $284,164 |
| Stockholders' equity | -$330,682 | -$310,988 | -$297,628 | -$260,539 | -$252,557 |
| Cash and investments | $2,932 | $1,530 | $1,889 | $6,287 | $15,616 |
| Total debt | $340,624 | $331,624 | $318,624 | $284,164 | $284,164 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Aug 10, 2026 | Jun 30, 2026 |
| 10-Q | Quarterly report | May 12, 2026 | Mar 31, 2026 |
| 10-K | Annual report | Mar 25, 2026 | Dec 31, 2025 |
| 10-Q | Quarterly report | Nov 7, 2025 | Sep 30, 2025 |
| 10-Q | Quarterly report | Aug 14, 2025 | Jun 30, 2025 |
| 10-Q | Quarterly report | May 13, 2025 | Mar 31, 2025 |
All 71 Nika Pharmaceuticals, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.